KR100561362B1 - Cosmetic composition comprising Umbilicaria escuenta Minks extracts - Google Patents

Abstract

The present invention relates to a cosmetic composition containing a mushroom extract (Umbilicaria escuenta Minks) as a cyclooxygenase inhibitory active ingredient, the composition is excellent in anti-inflammatory effect and its active ingredient is a natural extract, useful as a skin cosmetic, Formulation stability is excellent.

Stone mushroom, cosmetics, cyclooxygenase

Description

Cosmetic composition containing extracts of mushrooms {Cosmetic composition comprising Umbilicaria escuenta Minks extracts}

The present invention relates to a cosmetic composition containing a mushroom extract (Umbilicaria escuenta Minks) as a cyclooxygenase inhibitory active ingredient, in particular a cosmetic composition containing a mushroom extract having an excellent anti-inflammatory effect.

Cosmetics are used to keep skin healthy, improve it, protect it from external irritation, and beautify it. However, cosmetic compositions have been added because ingredients that cause skin irritation are indispensable for the formulation. For example, perfumes, solubilizers and emulsifiers, preservatives, sunscreens and other ingredients added for the effect of increasing efficacy belong to this. These ingredients can be the causative agents of skin irritation, rashes, and edema (Maybach, H. I., Contact Dermatitis, 6; 369-404, 1980).

In particular, recently, cosmetics have been greatly required for the functionality of the skin, but the side effects on the skin, but cosmetic development using the ingredients necessary to exhibit excellent functionality has been made. Therefore, there is a need for the development of a substance having an excellent anti-inflammatory effect in order to reduce skin side effects caused by irritant ingredients.

Inflammation indicates pain, fever, redness, swelling, etc. due to damage to biological tissues. Histologically, blood flow and permeability of blood vessels increase, causing exudation of plasma proteins and movement of white blood cells to inflammatory sites. Causes of inflammation include physical factors such as trauma, burns, frostbite, and radioactivity, chemical factors such as acids, and immunological factors due to antibody reactions. This happens. As vasodilation and permeability are enhanced by various chemical mediators secreted by inflammatory response-stimulated cells stimulated by the inflammatory source, antibodies, complement, plasma, and phagocytic cells flock to the site of inflammation, healing and defending the wound. It works.

Inflammatory mediators include vaso-active amines, vaso-active polypeptides, and other mediators. Vascular amines include histamine and three secreted from mast cells. Letonin and the like mainly serves to promote vasodilation and permeability. Vascular functional polypeptides such as kinin, plasmin, and complement compose vasoconstriction and chemotaxis, and other lymphokines such as interleukin-6 (IL-6). And arachidonic acid are responsible for the inflammatory response. Arachidonic acid, produced from membrane phospholipids by phospholipase A2 (PLA2) activated by an inflammatory source, is again produced by prostaglandin by cyclooxygenase (COX). Metabolism causes various inflammatory reactions (see Thomas. R., Rev. Physiol. Biochem. Pharmacol., 100, 1984).

Materials used for anti-inflammatory purposes to date include nonsteroidal flufenamic acid, ibuprofen, benzydamine, indomethacin, and prednisolone as a steroid system. ), Dexamethasone (see, eg, Chang-jong Kim, Pathophysiology, Hallym Co., p61-69, 1988), allantoin, azulene, ε-aminokiproic acid, hydrocortisone, licoriceic acid and its derivatives (β-glycol) Chilchinic acid, glychilechin acid derivatives) are known to be effective in anti-inflammatory (Ref .: Ministry of Gwangjeongjeong, New Cosmetics, Namsan Sugar, p162, 1933). However, the existing anti-inflammatory substances have a problem such as lowering the stability of the formulation, poor solubility or limited usage. In addition, many of these compounds are often accompanied by side effects, and in recent years, efforts to develop anti-inflammatory substances from natural products have been actively made. For example, Korean Patent Publication No. 2002-63479 discloses a composition for treating dermatitis containing isoflavone of soybean.

Therefore, the main object of the present invention is to provide a natural cosmetic composition having excellent salt-containing effect in view of the above-mentioned problems of the prior art.

Another object of the present invention to provide a cosmetic composition containing a mushroom extract.

In the study of the present inventors to solve the above problems, the anti-inflammatory action of the various natural extracts found that, as a result, the mushroom extract has a strong cyclooxygenase inhibitory effect, even in animal experiments against this It was found that showing an inflammatory action, and also to the fact that the cosmetic composition to which the extract is added to express an excellent anti-inflammatory effect was completed the present invention.

Therefore, according to the present invention, there is provided a composition for inhibiting cyclooxygenase, which contains a fungus extract as an active ingredient, in particular a cosmetic composition containing an anti-inflammatory fungus extract.

Hereinafter, the present invention will be described in more detail.

Seok-i mushroom is a kind of lichen (地 석) which is a genus of seok-ki and seok-ki. A leafy leaf growing on rocks in deep mountains. It is called a stone because it is like an ear attached to a rock. The lichen is 3-10cm in diameter (sometimes 30cm) in broad monologues, almost circular and leathery.

Preparation of the extract of the shiitake mushroom can be obtained through various methods known in the art. For example, water mushrooms, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (e.g. methanol, ethanol, propanol, butanol, etc.), acetone, ethyl acetate, chloroform or 1,3-butylene glycol as extraction solvent Extracts can be prepared. Of course, as well as the above-described extracting solvent, as well as the above-described extracting solvent, it can be obtained from the extract of the shiitake mushroom having substantially the same effect, and these methods are well known in the art.

The mushroom extract as a material for extraction may be used by drying it or may be used as it is, and preferably used by drying. As a drying method, natural drying or a hot air drying method can be used.

In the present invention, the shiitake mushroom extract includes not only the extract by the aforementioned extraction solvent, but also an extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using ultrafiltration membranes having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). The fraction is also included in the extract of the shiitake mushroom of the present invention. The mushroom extract of the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure, freeze drying or spray drying.

The stone mushroom extract of the present invention is excellent in cyclooxygenase inhibitory activity and anti-inflammatory effect and is extracted from natural substances, as will be apparent from the examples described below, and thus can be safely added to products to which cyclooxygenase inhibitory activity is to be given. have. For example, it can be applied to pharmaceutical compositions, cosmetic compositions, food compositions and the like. Therefore, the cyclooxygenase inhibitory composition in the present invention is used to mean such compositions.

The content of the fungus extract in the cyclooxygenase inhibitory composition of the present invention is an effective amount that the extract can be added to the composition to exhibit a cyclooxygenase inhibitory effect.

Hereinafter, the cosmetic composition will be described in order to help the understanding of the present invention, but it should be understood that the present invention is not limited thereto.

The cosmetic composition of the present invention is to contain the mushroom extract as an active ingredient for cyclooxygenase inhibition.

The content of the fungus extract in the cosmetic composition of the present invention is more than an effective amount that can exhibit a cyclooxygenase inhibitory effect. In particular, the content of the mushroom extract in the present cosmetic composition is 0.001% -10% (w / w), preferably 0.01% -3% (w / w) on a dry weight basis. When the content of the fungus extract in the cosmetic composition is less than the lower limit of the above range, it is difficult to expect a substantial cyclooxygenase inhibitory effect, and when the upper limit of the above range is exceeded, the formulation and product stability may be poor.

The component contained in the cosmetic composition of the present invention may contain components conventionally used in cosmetic compositions in addition to the extract of Shiitake mushroom as an active ingredient. Conventional adjuvants such as, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers and the like.

The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art. For example, it may be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, and the like. It is not limited to this. More specifically, it may be prepared in the form of a flexible lotion, astringent lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

When the cosmetic formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components. Can be.

When the cosmetic formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular, in the case of a spray, additionally chlorofluorohydrocarbon, Propellant such as propane / butane or dimethyl ether.

When the cosmetic formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsion may be used as the carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan and the like can be used.

When the cosmetic formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

When the cosmetic formulation of the present invention is a surfactant-containing cleansing agent, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid. Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

Features and other advantages of the present invention as described above will become more apparent from the following examples (extraction examples, experimental examples and formulation examples). However, these extraction examples, experimental examples and formulation examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited by them according to the gist of the present invention is usually in the art. It will be self-evident for those who have knowledge of.

[Extraction example]

Shiitake mushroom extract was prepared in the following manner.

First, S. mushroom (Bioland, Korea) was washed in purified water and used to dry naturally in the shade. The purified water is water sterilized by shining ion-exchanged water purified by ion-exchange resin to an ultraviolet lamp to remove bacteria and metal ions.

The dried oyster mushroom was ground in powder form using a grinder to facilitate solvent extraction. Ethanol as an extraction solvent was added to the obtained mushroom powder. The amount of ethanol was 10 times the weight of the mushroom powder. Thereafter, a cooling condenser was installed to extract the active ingredient for 15 days at room temperature, filtered with 300 mesh filter cloth, and then aged at 5-10 ° C. for 7-10 days to ripen, followed by Whatman 5 filter paper. Filtered. The filtrate was dried at 70 ° C. using a rotary evaporator to prepare an extract.

Experimental Example 1 Cyclooxygenase Inhibitory Effect of the Mushroom Extract

Cyclooxygenase inhibitory effect was measured as follows on the fungus extract obtained in the above extraction example.

Cyclooxygenase was purchased from Pel Freeze biologicals (USA), and arachidonic acid (Sigma-aldrich fine chemicals, USA) was used.

First, 1100 μM arachidonic acid and 25 μg hemoglobin were added to Tris buffer (0.1 M, pH 8.0) to form a substrate, and 10,000 units of cyclooxygenase and mushroom extract were added at different concentrations. Cyclooxygenase activity was obtained by measuring initial oxygen consumption with a Yellow Spring Instrument company (model 53 oxygen monitor). Cyclooxygenase inhibition rate (Ia) was calculated | required by Formula (1). The results are shown in Table 1.

Ia = [(Control O2-Sample O2) / Control O2] x 100

Here, O 2 means initial oxygen consumption.

Concentration of Sago Mushroom Extract (㎍ / ㎖) % Cyclooxygenase inhibition 12.5 37.2 ± 15 25 64.2 ± 8 50 83.5 ± 11 100 98.1 ± 13

From the results of Table 1, it can be seen that the mushroom extract is excellent in the inhibitory effect on cyclooxygenase.

Experimental Example 2 Mouse Ear Edema Inhibitory Activity

In the present experimental example, when the mushroom extract according to the present invention was continuously applied, arachidonic acid was applied to the ears of mice (Balb / c) in order to measure how much edema is suppressed in response to the edema inducing factor. Inflammation and thickness were measured (Richard PG, Alan JL et al., Agents and Actions, Vol. 17, 2, 1985).

Before application of the sample, the ears of the mouse were washed clean with ethanol, and the sample was continuously applied with 20 µl once a day for 4 days. After 1 hour of the last application, ethanol was applied to the left ear and 2 mg / ear of arachidonic acid was applied to the right ear. After 1 hour, the degree of edema of both ears was repeated three times with a micrometer.

The anti-inflammatory effect was determined as the degree of edema inhibition based on the arachidonic acid treatment group and the results are shown in Table 2. On the other hand, for comparison, Indomethacin, which is well known as a non-steroidal anti-inflammatory agent, was used to compare with the case of using the fungus extract. Inhibition rate (Ib) was calculated by the equation (2).

Ib (%) = (A-B) / A × 100

A: Ear without sample (thickness after arachidonic acid treatment-thickness before treatment)

B: Ear to which the sample was applied (thickness after arachidonic acid treatment-thickness before treatment)

sample Edema Inducing Factor Concentration (%) menstruum Ear thickness (㎛) Inhibition rate of inflammation (%) left side right Shiitake Mushroom Extract  Arachidonic acid 2mg / ear 0.3 ethanol 264 ± 6 508 ± 14 2.4 Shiitake Mushroom Extract 1.0 ethanol 275 ± 5 439 ± 15 34.4 * Shiitake Mushroom Extract 5.0 ethanol 261 ± 11 311 ± 8 80.0 * Indometacine 1.0 ethanol 274 ± 9 397 ± 14 50.8 * - - ethanol 277 ± 3 527 ± 11 -

*: There is a significant difference from the group treated with arachidonic acid only without adding sample at P <0.05.

As can be seen from the results of Table 2, 0.3%, 1.0%, and 5.0% of the mushroom extracts showed 2.4%, 34.4%, and 80.0% inhibition of inflammation, respectively. At concentrations above 1.0%, arachidonic acid showed a significant anti-inflammatory effect of 95%.

[Formulation example of cosmetic composition]

Hereinafter, examples of the cosmetic formulation of the present invention include a softening lotion, a convergent lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence and a pack, but the formulation of the present invention is not limited thereto.

Formulation Example 1 Flexible Lotion

A flexible cosmetic composition as shown in Table 3 was prepared.

ingredient Content (% by weight) Shiitake Mushroom Extract 0.1 glycerin 6.0 1,3-butylene glycol 3.0 PEG 1500 1.0 Allantoin 0.1 DL-panthenol 0.3 EDTA-2Na 0.02 Benzophenone-9 0.04 Sodium hyaluronate 5.0 ethanol 10.0 Octicdodeceth-16 0.2 Polysorbate 20 0.2 Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Formulation Example 2: Convergence Lotion

A convergent longevity composition was prepared in a composition as shown in Table 4.

ingredient Content (% by weight) Shiitake Mushroom Extract 0.1 glycerin 2.0 1,3-butylene glycol 2.0 Allantoin 0.2 DL-panthenol 0.2 EDTA-2Na 0.02 Benzophenone-9 0.04 Sodium hyaluronate 3.0 ethanol 15.0 Polysorbate 20 0.3 Witch hazel extract 2.0 Citric acid a very small amount Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Formulation Example 3: Nutritional Lotion

A nutrient cosmetic composition was prepared with a composition as shown in Table 5.

ingredient Content (% by weight) Shiitake Mushroom Extract 0.3 Glyceryl Stearate SE 1.5 Stearyl alcohol 1.5 lanolin 1.5 Polysorbate 1.3 Sorbitan stearate 0.5 Cured Vegetable Oil 1.0 Mineral oil 5.0 Squalane 3.0 Trioctanoine 2.0 Dimethicone 0.8 Tocopherol Acetate 0.5 Carboxyvinyl Polymer 0.12 glycerin 5.0 1,3-butylene glycol 3.0 Sodium hyaluronate 5.0 Triethanol amine 0.12 Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Formulation Example 4: Nutrition Cream

A nourishing cream composition was prepared in a composition as shown in Table 6.

ingredient Content (% by weight) Shiitake Mushroom Extract 0.3 Lipophilic monostearate 2.0 Cetearyl Alcohol 2.2 Stearic acid 1.5 Beeswax 1.0 Polysorbate 60 1.5 Sorbitan stearate 0.6 Cured Vegetable Oil 1.0 Squalane 3.0 Mineral oil 5.0 Trioctanoine 5.0 Dimethicone 1.0 glycerin 5.0 Betaine 3.0 Triethanolamine 1.0 Sodium hyaluronate 4.0 Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Formulation Example 5: Massage Cream

Massage cream composition was prepared in a composition as shown in Table 7.

ingredient Content (% by weight) Shiitake Mushroom Extract 0.3 Lipophilic Monostearic Acid Glycerin 1.5 Stearyl alcohol 1.5 Stearic acid 1.0 Polysorbate 60 1.5 Sorbitan stearate 0.6 Isostearyl isostearate 5.0 Squalane 5.0 Mineral oil 35.0 Dimethicone 0.5 Hydroxyethyl cellulose 0.12 glycerin 6.0 Triethanolamine 0.7 Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Formulation Example 6: Essence

An essence composition was prepared with the composition as shown in Table 8.

ingredient Content (% by weight) Shiitake Mushroom Extract 0.3 glycerin 10.0 Betaine 5.0 PEG 1500 2.0 Allantoin 0.1 DL-panthenol 0.3 EDTA-2Na 0.02 Benzophenone-9 0.04 Hydroxyethyl cellulose 0.1 Sodium hyaluronate 8.0 Carboxyvinyl Polymer 0.2 Triethanol amine 0.18 Octyldodecanol 0.3 Octyldodeceth-16 0.4 ethanol 6.0 Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Formulation Example 7: Pack

A pack composition was prepared with the composition as shown in Table 9.

ingredient Content (% by weight) Shiitake Mushroom Extract 0.3 Polyvinyl alcohol 15.0 Cellulose gum 0.15 glycerin 3.0 PEG 1500 2.00 Chicdestrin 0.15 DL-panthenol 0.4 Allantoin 0.1 Glycyrisin Monoammonium 0.3 Nicotinamide 0.5 ethanol 6.0 PEG 40 Cured Castor Oil 0.3 Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Experimental Example 4 Stability Test of the Formulation

For the stability test of the formulation of the cosmetic composition of the present invention, the nutritional cream of Formulation Example 4 containing 0.3% by weight of the shiitake mushroom extract and the nutritional cream of the Example 4 nutritional cream replacing the shiitake mushroom extract of Formulation Example 4 with purified water as a comparative example After keeping for 12 weeks in an opaque glass container in a thermostatic chamber maintained at a constant and completely shaded refrigerator kept at 4 ℃ constant for 12 weeks, the degree of separation and discoloration was measured. The degree of separation and discoloration of the formulation was evaluated by classifying into the following six grades. The evaluation results are shown in Table 10.

* Evaluation criteria for discoloration of formulation

0: no change 1: very little separation (discoloration)

2: little separation (discoloration) 3: little separation (discoloration)

4: severely separated (discolored) 5: extremely severely separated (discolored)

Temperature Degree of discoloration of the formulation Cream of Formulation Example 4 Comparative cream 45 ℃ 0 0 0 ℃ 0 0

From the results of Table 10, it can be seen that the cosmetic compositions of Formulation Example 4 and Comparative Example do not discolor and separate, and thus there is no abnormality in the stability of the formulation.

As described above in detail a specific part of the present invention, it is apparent to those skilled in the art that the specific technology is only a preferred embodiment, which is not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

As described in detail above, the composition of the present invention containing a mushroom extract as a cyclooxygenase inhibitory active ingredient can be applied as a skin cosmetic because of its excellent anti-inflammatory effect, there is an advantage such as excellent formulation stability of the cosmetic composition .

Claims (4)

(delete) A cosmetic composition comprising a mushroom extract containing an effective amount of a mushroom extract as a cyclooxygenase inhibitory active ingredient. The cosmetic composition according to claim 2, wherein the content of the mushroom extract is 0.001-10.0% by weight based on the total dry weight of the composition. 3. The composition of claim 2 selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays. Cosmetic composition containing a mushroom extract, characterized in that it has a formulation.